Team-science is essential to moving therapies forward. We first have to understand changes that occur with disease progression, and then we can ask how therapies change this course and promote tolerance. We work with scientists and clinicians with a range of expertise to assess the phenotype and function of immune cells in natural history and clincial trial settings with a focus on single cell technologies.
We have found that tolerogenic therapies can modulate the number, type and function of CD4 Treg or CD8 exhausted T cells. However, specific changes that associate with better outcome and how tolerance is conferred remain poorly understood. We are exploring these mechanisms across therapeutic modalities and autoimmune diseases.
Additional Research Projects
Discover more research projects from the
Long Lab.
Drivers of CD8 T cells exhaustion in autoimmunity
We are investigating what factors promote exhausted CD8 T cells, a cell type associated with better outcome in T1D.
Impact of IL-2/IL-2R signaling in T1D
We are investigating the molecular mechanisms underlying reduced IL-2R singaling in effector CD4 T cells of T1D subjects.
